Clinical trial
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating…
NCT00220740 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00220740 |
|---|---|
| Title | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| Official title | Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy |
| Acronym | ICE |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
| Intervention type | Drug |
| Interventions | Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP) |
| Enrollment | 117 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 23, 2016 |
| Countries | Argentina, Canada, Czechia, Germany, Israel, Italy, Mexico, Poland, Serbia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: